Return to CAP Home

  CAP, CDC, and ASCO Combine
  Forces to Improve Reporting
  of Molecular Tumor Markers


Posted May 8, 2012

CAP, the Centers for Disease Control and Prevention (CDC), and the American Society of Clinical Oncology (ASCO) have identified a need for standardization and consistency when reporting on ancillary lab studies, including many different types of molecular testing for cancer diagnosis, treatment, and follow-up. The three agencies joined forces to form the CAP-hosted, interorganizational Ancillary Studies Workgroup (ASWG). The ASWG will consist of pathologists from CAP and the Association for Molecular Pathology (AMP), clinical oncologists from the ASCO, cancer registrars, informaticists, and molecular pathology experts from multiple national organizations.

The ASWG will create standardized laboratory reporting protocols intended for use by pathologists when reporting on tumor specimens. These new protocols incorporated into new templates will use the familiar eCC approach. This process will help guide the CDC’s efforts in standardizing laboratory reporting for new initiatives in comparative effectiveness research. Three checklists for Breast, Lung, and Colon will be piloted by the end of 2012, at which time user feedback will be actively solicited.